Jerini AG is a pharmaceutical company based in Berlin, Germany, which focuses on the discovery and development of novel peptide-based drugs. Using a proprietary technology platform, Peptides-to-Drugs (P2D), Jerini pursues disease indications for which limited, inadequate, or no treatment options exist. As a result, Jerini has established a drug pipeline composed of its own programs as well as others in collaboration with partners. Jerini's commercialization strategy is to market new drugs in niche indications independently and in larger indications with partners.
Jerini started operations in 1994. Subsidiaries are JPT Peptide Technologies GmbH and Jerini US, Inc. Jerini is listed on the Prime Standard of the Frankfurt Stock Exchange (JI4), and has raised a total of over 130 million Euro in public and private financing to date.
Jerini plans to broaden the therapeutic potential of Firazyr by addressing additional disease indications in which the pathophysiological role of elevated bradykinin levels has been established. Based on data obtained in Phase IIa clinical studies, Jerini and its US partner Kos Pharmaceuticals (now part of Abbott) are evaluating Icatibant's therapeutic potential in asthma and liver cirrhosis. Jerini has also obtained positive preclinical data demonstrating Icatibant's effect in severe burn models. The FDA has also granted Jerini orphan designation in this indication.
Jerini's proprietary Peptides-to-Drugs (P2D) technology is used to identify peptide drug lead structures and systematically transform them into peptidomimetic (injectable) and small-molecule (oral) drugs, depending on the indication. As a result, Jerini is able to develop novel drug candidates against disease targets that are difficult to address using traditional discovery methods. The ability to create both peptidomimetic and small-molecule drug candidates facilitates parallel development of acute and chronic treatment possibilities for the same disease target, providing multiple business and partnering opportunities.
Collaboration agreements exist with Alcon Research Ltd., Baxter AG, Sanofi Aventis and Shire Limited.